Drugs / CD45RA-depleted DLI
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07672964 | Jul 2026 → Jul 2027 expected | hematopoietic and lymphoid cell neoplasm | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04558736 | Jan 2021 → Jul 2029 expected | aplastic anemia, bone marrow failure syndrome | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT03849651 | Jan 2019 → Aug 2024 overdue | Hodgkins lymphoma, T-cell and NK-cell neoplasm, acute lymphoblastic leukemia, acute myeloid leukemia +3 | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07867769 Comparator | Oct 2026 → Oct 2029 expected | disease related to hematopoietic stem cell transplant | Hong Kong Children's Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD45RA Depleted DLI | “special type of donor immune cells (called CD45RA Depleted DLI)” NCT07672964 ↗ |
| Modality | Cell therapy | “additional infusion of donor memory cells (CD45RA-depleted) after donor cell engraftment.” NCT03849651 ↗ |
| Route | Intravenous | “infusion IV” NCT03849651 ↗ |